Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Acorda Provides Financial and Pipeline Update for Third Quarter 2016
October 27, 2016 6:01 AM EDTAMPYRA® (dalfampridine) 3Q 2016 Net Revenue of $128.8 Million; 10% Increase over 3Q 2015 Net Revenue of $117.0 Million Data for Dalfampridine in Post-Stroke Walking Difficulties by Year End 2016 and Phase 3 data for CVT-301 for OFF Periods in Parkinsons Disease in Q1 2017
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the third quarter ended September 30,... More
